ATE219081T1 - Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung - Google Patents

Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung

Info

Publication number
ATE219081T1
ATE219081T1 AT97905544T AT97905544T ATE219081T1 AT E219081 T1 ATE219081 T1 AT E219081T1 AT 97905544 T AT97905544 T AT 97905544T AT 97905544 T AT97905544 T AT 97905544T AT E219081 T1 ATE219081 T1 AT E219081T1
Authority
AT
Austria
Prior art keywords
carbanium
azabicyclic
acid esters
therapeutic use
therapeutic
Prior art date
Application number
AT97905544T
Other languages
German (de)
English (en)
Inventor
John Macor
Edwin Wu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE219081T1 publication Critical patent/ATE219081T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT97905544T 1996-02-23 1997-02-21 Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung ATE219081T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600683A SE9600683D0 (sv) 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy
PCT/SE1997/000294 WO1997030998A1 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy

Publications (1)

Publication Number Publication Date
ATE219081T1 true ATE219081T1 (de) 2002-06-15

Family

ID=20401517

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905544T ATE219081T1 (de) 1996-02-23 1997-02-21 Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung

Country Status (26)

Country Link
US (2) US5998429A (enExample)
EP (1) EP0885221B1 (enExample)
JP (1) JP2000505452A (enExample)
KR (1) KR19990087184A (enExample)
CN (1) CN1063749C (enExample)
AR (1) AR005876A1 (enExample)
AT (1) ATE219081T1 (enExample)
AU (1) AU706944B2 (enExample)
BR (1) BR9707616A (enExample)
CA (1) CA2246051A1 (enExample)
CZ (1) CZ289110B6 (enExample)
DE (1) DE69713295T2 (enExample)
EE (1) EE9800250A (enExample)
HU (1) HUP9901273A3 (enExample)
ID (1) ID15969A (enExample)
IL (2) IL125620A (enExample)
IS (1) IS4830A (enExample)
NO (1) NO983711D0 (enExample)
NZ (1) NZ331145A (enExample)
PL (1) PL328614A1 (enExample)
RU (1) RU2172739C2 (enExample)
SE (1) SE9600683D0 (enExample)
SK (1) SK102798A3 (enExample)
TR (1) TR199801642T2 (enExample)
WO (1) WO1997030998A1 (enExample)
ZA (1) ZA971082B (enExample)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
FR2804430B1 (fr) * 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001282874A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
AU2001284645A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
JP2004506734A (ja) * 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
JP2005504059A (ja) * 2001-08-24 2005-02-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
BR0212477A (pt) * 2001-09-12 2004-08-24 Upjohn Co 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
OA12708A (en) * 2001-10-02 2006-06-26 Upjohn Co Azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6919359B2 (en) 2001-11-08 2005-07-19 Pfizer Inc Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
US6951868B2 (en) 2001-11-09 2005-10-04 Pfizer Inc. Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
IL162153A0 (en) 2001-12-14 2005-11-20 Target Discovery Methods and compositions for treatment of central nervous systemdisorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MXPA04007936A (es) 2002-02-15 2004-11-26 Upjohn Co Compuestos de aril-sustituidos para el tratamiento de enfermedades.
CA2476681A1 (en) * 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
US6894042B2 (en) * 2002-02-19 2005-05-17 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
MXPA04007083A (es) * 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
US7176198B2 (en) 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
JP2006501246A (ja) 2002-08-30 2006-01-12 メモリー・ファーマシューティカルズ・コーポレイション 神経変性疾患の治療において有用なアナバセイン誘導体
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
SK288115B6 (sk) 2002-09-25 2013-09-03 Memory Pharmaceuticals Corporation Indazoles, pharmaceutical compositions comprising them and their use
EP1562959A2 (en) * 2002-11-01 2005-08-17 Pharmacia & Upjohn Company LLC Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CN102657651A (zh) * 2002-12-06 2012-09-12 范因斯坦医学研究院 用α 7受体结合胆碱能激动剂抑制炎症
BRPI0408815A (pt) * 2003-03-28 2006-04-04 Pharmacia & Upjohn Co Llc moduladores alostéricos positivos do receptor nicotìnico da acetilcolina
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
DE10334724A1 (de) * 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
CA2539811A1 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
US20050137217A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
EP1697378B1 (en) 2003-12-22 2007-11-21 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
FR2865208B1 (fr) * 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
EP2336128A1 (en) 2004-03-25 2011-06-22 Memory Pharmaceuticals Corporation Benzoisothiazoles and preparation and uses thereof
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2006001894A1 (en) 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
NZ551712A (en) 2004-05-07 2010-07-30 Memory Pharm Corp 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
ES2342675T3 (es) 2004-12-22 2010-07-12 Memory Pharmaceuticals Corporation Ligandos del receptor alfa-7 nicotinico contra enfermedades relacionadas con el snc.
CA2593079C (en) 2004-12-27 2014-08-19 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
NZ565628A (en) 2005-08-22 2011-03-31 Targacept Inc Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TWI404532B (zh) * 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2119716A4 (en) * 2007-02-09 2011-06-01 Astellas Pharma Inc AZA BRIDGE CYCLE COMPOUND
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
KR101565469B1 (ko) 2007-10-01 2015-11-03 코멘티스, 인코포레이티드 알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1ｈ-인돌-3-카르복실레이트 유도체
HRP20130749T1 (en) 2008-02-13 2013-10-11 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
SI2307389T1 (sl) 2008-06-20 2013-04-30 Astrazeneca Ab Derivat diabenzotiazepina in njegova uporaba
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2391628A4 (en) * 2009-01-28 2012-10-10 Astrazeneca Ab 2-AZA-BICYCLOÝ2.2.1¨HEPTANE COMPOUNDS AND USES THEREOF
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
FR2948368B1 (fr) * 2009-07-21 2011-07-22 Servier Lab Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2011079309A2 (en) 2009-12-23 2011-06-30 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
CA3057923A1 (en) 2010-05-17 2011-11-24 Patricia Oliver-Shaffer A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US10449177B2 (en) 2010-08-19 2019-10-22 Buck Institute For Research On Aging Methods of treating mild cognitive impairment (MCI) and related disorders
CN103619405B (zh) 2011-05-09 2015-11-25 赛博恩特医疗器械公司 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
MX358512B (es) 2012-05-08 2018-08-24 Forum Pharmaceuticals Inc Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
CN105189491B (zh) 2013-03-15 2018-07-06 建新公司 制备葡萄糖基神经酰胺合酶抑制剂的方法
CN105324372B (zh) 2013-06-21 2018-03-06 武田药品工业株式会社 作为前动力蛋白受体调节剂的1‑磺酰基哌啶衍生物
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
TW201617342A (zh) 2014-07-11 2016-05-16 阿法馬根公司 調節α７活性之啶類
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTIVE CHARGING SYSTEMS
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
DE102017210141A1 (de) 2017-06-16 2018-12-20 Henkel Ag & Co. Kgaa Portion zur Bereitstellung tensidhaltiger Flotten
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
EP3952982B1 (en) 2019-04-12 2024-03-27 Setpoint Medical Corporation Vagus nerve stimulation system to treat neurodegenerative disorders
CA3154313A1 (en) * 2019-11-15 2021-05-20 Dong-Hoon Kim Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
US12338237B2 (en) 2019-11-15 2025-06-24 Yuhan Corporation Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
WO2021156769A1 (en) 2020-02-03 2021-08-12 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
CA3186766A1 (en) 2020-07-24 2022-01-27 Danielle Combessis Pharmaceutical compositions comprising venglustat
CA3216293A1 (en) * 2021-05-11 2022-11-17 Dong-Hoon Kim Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the sam
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
JP2025537478A (ja) * 2022-10-24 2025-11-18 ユーハン・コーポレイション ジメチル－２，３－ジヒドロ－１ｈ－インデン誘導体の新規塩およびその製造方法
CA3268123A1 (en) * 2022-10-24 2024-05-02 Yuhan Corp IMPROVED PROCESSES FOR PREPARING DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVES
KR20250117295A (ko) * 2024-01-26 2025-08-04 주식회사유한양행 고셔병의 예방 또는 치료용 약제학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU482990A1 (ru) * 1973-09-03 1978-04-15 Предприятие П/Я Г-4059 Способ получени 1,4-диазабицикло(2,2,2)-октана
DE8817121U1 (de) * 1988-11-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Quinuclidine
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
US5530018A (en) * 1994-02-04 1996-06-25 G. D. Searle & Co. Meso-azanoradamantanes
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives

Also Published As

Publication number Publication date
KR19990087184A (ko) 1999-12-15
EE9800250A (et) 1999-02-15
US5998429A (en) 1999-12-07
CA2246051A1 (en) 1997-08-28
CZ289110B6 (cs) 2001-11-14
AU706944B2 (en) 1999-07-01
DE69713295D1 (de) 2002-07-18
HUP9901273A3 (en) 2000-06-28
NO983711L (no) 1998-08-13
CN1211983A (zh) 1999-03-24
DE69713295T2 (de) 2003-01-09
EP0885221A1 (en) 1998-12-23
WO1997030998A1 (en) 1997-08-28
IL125620A (en) 2001-09-13
AR005876A1 (es) 1999-07-21
HUP9901273A2 (hu) 1999-07-28
IL125620A0 (en) 1999-04-11
SE9600683D0 (sv) 1996-02-23
CN1063749C (zh) 2001-03-28
NZ331145A (en) 2000-02-28
TR199801642T2 (xx) 1998-11-23
ID15969A (id) 1997-08-21
IS4830A (is) 1998-08-20
NO983711D0 (no) 1998-08-13
BR9707616A (pt) 1999-07-27
AU2238797A (en) 1997-09-10
EP0885221B1 (en) 2002-06-12
SK102798A3 (en) 1999-01-11
HK1017357A1 (en) 1999-11-19
ZA971082B (en) 1997-08-25
CZ265998A3 (cs) 2000-02-16
US6054464A (en) 2000-04-25
JP2000505452A (ja) 2000-05-09
RU2172739C2 (ru) 2001-08-27
IL137585A0 (en) 2001-07-24
PL328614A1 (en) 1999-02-01

Similar Documents

Publication Publication Date Title
ATE219081T1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
ID19222A (id) Proses karbonilasi dengan dikatalisa iridium untuk pembuatan asam asetat
DE69618337D1 (de) Verfahren zur Fahrstabilitätserhöhung
DE69633869D1 (de) Molybdan-modifierte vanadin-phosphor-oxidkatalysatoren zur herstellung von maleinsäureanhydrid
FI971991L (fi) 2-syaaniakryylihappoesterit
ID21753A (id) Proses pembuatan asam asetat
DE69528011D1 (de) Verfahren zur Pflege der Nägel
DE69702550D1 (de) Verfahren zur Herstellung von peroxiperfluoropolyxyalkylene
DE69500868D1 (de) Verfahren zur Herstellung von Carbonsäureestern
DE69423487D1 (de) Einrichtung zur aquakultur
EP1039883A4 (en) METHOD FOR TREATING APOLIPOPROTEIN E CONDITIONAL DISEASES
DE69708032D1 (de) Verfahren zur Herstellung von Trimethylcatecholdiestern
FI971973L (fi) Menetelmä kompleksiesterien valmistamiseksi ja puhdistamiseksi
DE59610221D1 (de) Verfahren zur Herstellung von 2-Acetyl-gamma-butyrolacton
FI955328L (fi) Menetelmä formyylikarboksyylihappoestereiden valmistamiseksi
DE69703764D1 (de) Verfahren zur Herstellung von N-Acetonylbenzamide
DE69526841D1 (de) Verfahren zur Wiedergabe
DE59509820D1 (de) Mehrkernige Phosphorsäureester
ID17052A (id) Turunan-turunan asam asetat terapeutik
DE69721812D1 (de) Verfahren zur herstellung optisch aktiver 3-quinuclidinol derivate
DE69700477D1 (de) Verfahren zur Herstellung von optisch aktivem 4-Hydroxy-2-Pyrrolidon
DE59706245D1 (de) Verwendung von milchsäureestern
DE69703599D1 (de) Verfahren zur Herstellung von 2-H-Heptafluorpropan
DE59705359D1 (de) Verfahren zur Herstellung von 2-Cyanoethyl-phosphinsäureestern
DE59705748D1 (de) Verfahren zur Herstellung von Cyclopentanolen